# A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

> **NCT05147493** · PHASE2 · UNKNOWN · sponsor: **Hellenic Society of Hematology** · enrollment: 51 (estimated)

## Conditions studied

- Multiple Myeloma
- Renal Impairment
- Neoplasms, Plasma Cell
- Neoplasms by Histologic Type
- Neoplasms
- Paraproteinemias
- Blood Protein Disorders
- Hematologic Diseases

## Interventions

- **DRUG:** Isatuximab
- **DRUG:** Bortezomib
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT05147493
- **Lead sponsor:** Hellenic Society of Hematology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04
- **Primary completion:** 2024-12
- **Final completion:** 2025-02
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2022-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05147493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05147493, "A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05147493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*